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Abstract
Purpose of Review Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical
outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the
treatment approaches used for these different subgroups.
Recent Findings Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the
suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to
FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will
be translated into durable remissions.
Summary Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the
majority of patients, early after diagnosis and with curative intent.
Keywords Chronic lymphocytic leukaemia . Chemoimmunotherapy . Ibrutinib . Venetoclax . Future
Introduction
Chronic lymphocytic leukaemia (CLL) is the commonest leu-
kaemia in the world, with 4.9 new diagnosis per 100,000 per
year in the UK and USA. The malignant clonal proliferation
and accumulation of mature B-lymphocytes is predominantly
identified in older patients with a median age of 74 at diagno-
sis [1, 2]. The majority of patients are monitored with a ‘watch
and wait approach’ until the balance of risks and benefits
favours treatment initiation. In some cases, treatment may
never be needed whilst in others, the disease is more aggres-
sive with rapid progression and death from disease-related
causes a few years after diagnosis [3]. This disparity in
outcome highlights the heterogeneity of CLL and the impor-
tance of risk stratification to guide treatment decisions. unlike,
its myeloid counterpart—chronic myeloid leukaemia—a
pathognomonic driving mutation, BCR-ABL, has not been
identified, and this slightly delayed the development of
targeted therapies. However, over the last two decades, a
dramatic increase in our understanding of the pathogenesis
of the disease has led to the development of small molecule
inhibitors for CLL targeting the B cell receptor pathway and
the apoptotic regulator BCL2. Some of these newer thera-
pies appear to be so effective; they may provide a curative
option for patients, previously treatment aimed to establish
disease control. In this review, we will briefly discuss recent
advances in our understanding of the molecular pathology
of CLL and then, in more detail, the way that CLL is
managed in the UK.
New Developments in the Understanding
of the Pathogenies of CLL
Our understanding of the genetics of CLL and the implica-
tions on patient outcome began with the publication by Doner
et al. in 2000which identified four recurrent genetic lesions by
fluorescence in situ hybridisation (FISH) and showing that
their presence predicted disease prognosis. It was found that
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a lesion at 17p13 and 11q23 indicated a poor prognosis com-
pared with 13q14 and 12q; this formed the basis of the FISH
probe set used routinely during CLL diagnostics [4]. The util-
ity of FISH is limited by the need to identify particular region
to probe and by the number of probes that can be used at one
time. Unlike FISH, G-banding karyotyping which can be ap-
plied to all the chromosomes simultaneously, required cells to
be in metaphase, various compounds have been used to raise
the yield of metaphase cells in CLL—the combination of
DSp30/IL2 has shown to do so without inducing artefactual
chromosomal aberrations [5, 6]. Using this technique, it has
been demonstrated 16–19% of patients have a complex kar-
yotype (3 > abnormalities) that this predicts poor outcome in-
dependent of P53 status, and the presence of 5 of more is
associated with a P53 mutations and perhaps due to this
association, a more aggressive course [7]. These techniques
have been replaced in research by chromosomal micro arrays
and single nucleotide polymorphisms arrays which do not
require the cells to be in the cell cycle and whilst the
concordance of these approaches is reported in small studies,
their incorporation into large trials is awaited [8].
CLL patients can be categorised into two groups depending
on the mutational status, established by PCR or next genera-
tion sequencing, of the variable region immunoglobulin heavy
chain (IGHV) when compared with germline sequence.
During the process of VDJ rearrangement and somatic
hypermutation of B cells occurs within the germinal centres
generating receptors capable of recognising an extensive
range of antigens. IGHV-mutated (IGHV-M) CLL, with a mu-
tation status of > 2%, compared with germline sequence as an
immunophenotype and gene expression profile similar to that
of post GC CD27+, T cell dependent memory B cells. Whilst
IGHV-unmutated (IGHV-UM) CLL cells adopted a pheno-
type gene expression profile and epigenome that resemble a
GC-naïve CD27− B cell [9, 10]. This difference is reinforced
when comparing the BCRs of the two subtypes with IGHV-
UM carrying low affinity, poly-reactive and self-reactive
BCR, and IGHV-M has higher affinity, olio or mono reactive
receptors [11]. This may contribute to the poorer prognosis
seen with IGHV-UM CLL [12, 13].
Next generation sequencing confirmed that the mutational
rate in CLL is similar to that of other haematological cancers
and lower than solid malignancy, with each patients having a
small number of recurrently mutated driver genes—unsurpris-
ingly, many of the mutated genes identified in these studies are
involved in cell replication, DNA repair apoptosis and signal-
ling [14–17]. The subtypes, the 4 chromosomal abnormalities
discussed earlier have also been shown to be associated with
different recurrent gene mutations, similarly to IGHV status,
which may explain the heterogeneity in there clinical course.
For example, 17p13 deletion occurs with mutation of the re-
maining p53 resulting in homozygous inactivity and SF3B1, a
protein involved in the regulation of the spliceosome with 11q
deletion [18, 19]. In these studies, a quarter of patients had a
mutation in a gene involved in RNA splicing or repair—a
possible avenue for new drug development [20].
As well as identification of mutated genes in CLL, the
mechanisms of gene expression regulation have also been
studied. It is known that BCL2 an antiapoptotic protein is
overexpressed in CLL and that its expression increases with
chemotherapy [21–23]. BCL2 combines with BH3 and binds
to BIM, preventing BIM triggering apoptosis [24]. The recur-
rent deletion of 13q14 is seen in 50% of de novo CLL; it has
been shown that this deletion results in the loss of expression
of micro RNA (miRNA) 15-A/16-1 [25, 26]. As miRNA 15-
A and 16-1 normal interfere in the transcription of BCL2, their
loss contributes to its overexpression in CLL [27].
Interaction with other cells in the microenvironment is cru-
cial to the survival and replication of CLL cells, as shown by
the rapid apoptosis of CLL cells in vitro and the reduction in
this when co-cultured with non-tumoral bystander cells [11].
The lymph nodes can be the key site of CLL proliferation,
with higher activation of the NFKb and the BCR signalling
pathways crucial for this process than the bone marrow of
peripheral blood [28], whilst the bone marrow creates a pro-
tective niches preventing spontaneous and drug-induced apo-
ptosis cells [29, 30]. Interruption of these interactions may
force the cells into the peripheral circulation, therefore increas-
ing their susceptibility to drug-induced chemotherapy.
Treatment of Chronic Lymphocytic
Leukaemia in 2019
Most patients with CLL present with an incidental finding of a
lymphocytosis, they may have palpable lymphadenopathy or
organomegaly, bonemarrow involvement can lead to anaemia
and thrombocytopenia. Occasionally, patients may have the
constitutional B symptoms with an unexplained fever of over
38°, weight loss of > 10% in less than 6 months and night
sweats. A complication of CLL such as a high-grade disease
transformation, an autoimmune disease or a severe infection
may lead to its diagnosis [31].
The following diagnostic criteria are stipulated by the in-
ternational workshop of CLL (iwCLL) and reiterated in the
WHO classification of lymphoid neoplasms. The lympho-
cytes count in the peripheral blood must be greater than 5 ×
10 × 9, persistent for 3 months, and clonality of this popula-
tion must be shown by flow cytometry for light chain restric-
tion, CD5, CD23, CD79b and surface immunoglobulin ex-
pression with low levels of CD20. The presence of smudge/
smear cells, an artefact of blood film production, is a typical
finding in CLL [32]. If the WCC is less than 5 × 10/L with no
other signs of lymphoproliferative disorder, this constitutes
monoclonal B cell lymphocytosis which is thought as a pre-
cursor to CLL, with a rate of progression of 1% per year [33].
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Identification of a clonal population of mature B cells within
the lymph nodes or extranodal tissues without a peripheral
blood lymphocytosis is referred to as a small lymphocytic
lymphoma [34]. Fluorescence in situ hybridisation is used to
identify chromosomal rearrangements which can differentiate
CLL from other conditions such as mantle cell lymphoma as
well as helping with disease stratification.
When to Initiate Treatment
In addition to diagnostic criteria, the iwCLL guidelines dictate
when to initiate treatment, based on patients’ symptoms, full
blood counts and physical examination. The presence of con-
stitutional symptoms, progressive lymphocytosis, a doubling
time of less than 6 months, an Hb of less than 100 g/L or a
platelet count of less than 100 x 109/L as well as progressive or
symptomatic bulky lymphadenopathy/organomegaly or
treatment-resistant autoimmune thrombocytopaenia or anae-
mia are indications to start treatment [32]. In some circum-
stances, treatment may be initiated at diagnosis, but it is much
more common for patient to be monitored for signs of increas-
ing disease activity often over many years.
Patient Risk Stratification
Similar to the management of most malignancy, the most
suitable treatment for a patient with CLL is selected based
on genetic features of the disease itself—the presence of a
P53 mutation or 17p deletion and the mutational state of
the IGHV—and patient factors [35]. The algorithm for
treatment selection followed by haematologists in the
UK is shown in Fig. 1. Disruption of P53, a tumour sup-
pressor crucial in many cancers, is known to result in very
poor response to combination immunochemotherapy, and
therefore, patients are treated with molecular therapies
first line [18]. If the IGHV is unmutated, compared with
the germline sequence, this confers a poor survival risk
when compared with patient with a mutated IGHV [12,
13]. The co-morbidities and performance status of indi-
vidual patients are crucial in setting treatment goals and
treatment selection. Treatment success or disease progres-
sion is determined on similar criteria to treatment
initiation—repeat CT scans are not recommended out with
clinical trials. The identification of minimal residual dis-
ease (MRD) on peripheral blood or bone marrow aspirate
by flow cytometry, with a sensitivity of 0.01%, is becom-
ing increasingly important as MRD negativity after
chemoimmunotherapy is associated with prolonged
progression-free and overall survival—in the future, early
evidence of MRD negativity may allow for shorter treat-
ment regimens [36, 37].
U p o n t r e a t m e n t f a i l u r e o n c om b i n a t i o n
chemoimmunotherapy or ibrutinib, there are now several
available options for relapsed disease including the
PI3K inhibitor idelalisib and the BCL2 inhibitor
Venetoclax, also shown in Fig. 1.
Combination
Immunochemotherapy—Fludarabine,
Cyclophosphamide, Rituximab (FCR)
and Other CD20 Antibodies
Young fit patients, with a creatine clearance of greater than 70
and a comorbidity scale of 6 or less without P53mutations and
with mutated IGHV, are treated with combination
chemoimmunotherapy, fludarabine, cyclophosphamide and
rituximab (FCR) [38, 39]. Prior to the introduction of immu-
notherapy chlorambucil (CLB), an alkylating agent or
fludarabine, a purine analogue monotherapy was the mainstay
of treatment—the combination of these agents did not im-
prove response rates but did carry much higher haematologi-
cal toxicity [40]. The addition of cyclophosphamide to
fludarabine (FC) led to an improved progression-free survival
(PFS) and overall survival (OS) without an increase in serious
adverse events compared with fludarabine monotherapy [41].
The approval of rituximab—a monoclonal antibody targeting
CD20, a glycosylated cell surface protein expressed onmature
B cells—provided a treatment option for many B cell malig-
nancies. In the CLL8 trial, patients were randomised to receive
either FC or FCR, which gave a response rate of 85 and 92%
respectively. Particular subgroups of patients appear to have
particularly good long-term outcomes, those with a mutated
IGVH, del(13q), trisomy 12 or del(11q) or MRD negative
remission [42, 43•]. The durability of these remissions led to
the suggestion that FCR may be curative for some patients.
There is emerging evidence that reduced doses or 3 rather than
6 cycles result in non-inferior PFS and OSwith a lower burden
of cumulative toxicity [36].
Whilst FCR is known to result in longer PFS compared
with bendamustine and rituximab (BR) in younger patients,
the benefit was not seen in patients over 65—and a lower rate
of serious infections were seen in the BR cohort. Therefore, in
patients over 65 who do not qualify for ibrutinib BR tended to
be favoured, unless there is a contraindication to
bendamustine when chlorambucil rituximab could be used
accepting that this had a poorer response rate [44, 45]. The
CLL11 trial looked specifically at the treatment of older pa-
tients with co-morbidities and the impact of a new anti CD20
monoclonal antibody, obinutuzumab. Treatment with
obinutuzumab-CLB compared with R-CLB and CLB
monthotherapy increased response rates and prolonged PFS
(median PFS, 26.7 months with obinutuzumab-CLB vs
11.1 months with CLB alone; 16.3 months with R-CLB)
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[46]. Currently, results of a large clinical trial multicentre trial,
with over 900 participants are awaited, comparing single-
agent obinutuzumab and its combination with FC,
chlorambucil or bendamustine in untreated and relapsed
CLL is awaited; it is possible that obinutuzumab will replace
rituximab in the long-standing FCR regime [47, 48].
Bruton Tyrosine Kinase Inhibitors—Ibrutinib
The B cell receptor and downstream signalling pathways are
crucial to the survival and proliferation of malignant cells in
CLL. Unlike their healthy counterparts in CLL, signalling
from the B cell receptor is activated independently of appro-
priate antigen stimulation—autologous activation. Bruton ty-
rosine kinase (BTK) which is only slightly downstream of the
receptor itself activates the cell survival pathway NfK-B and
MAP kinases, its inhibition leads to apoptosis of CLL cells
[49]. Ibrutinib is an orally available small molecular inhibitor
that binds to BTK preventing its kinase activity. This affects
multiple signalling pathways and disrupts the interactions be-
tween CLL cells and the microenvironment leading to further
apoptosis.
Initially trialled in relapsed or refractory CLL, response
rates to ibrutinib were between 84 and 97% and complete
response rates were 12–23% [50]. This was independent of
previously identified poor prognostic factors including ad-
vanced stage disease, number of previous lines of treatment
and del 17(p). The RESONATE trial, a multicentre phase 3
open-label trial with 391 participants, compared ibrutinib with
an anti-CD20 antibody, ofatumumab, note no longer in use, in
a cohort of patients with relapsed CLL/SLL. Ibrutinib signif-
icantly improved the response rate, PFS and OS. The median
PFS of 8.1 months in the ofatumumab group whilst at
9.4 months, the median PFS had not been reached in the
ibrutinib group, PFS of 88% at 6 months [51]. RESONATE
2 showed that ibrutinib was more effective than single-agent
chlorambucil as a first-line treatment in patients aged over 65.
Ibrutinib significantly prolonged overall survival; estimated
survival rate at 24 months was 98% with ibrutinib and 85%
with chlorambucil, with a relative risk of death that was 84%
lower in the ibrutinib group. The overall response rate was
higher with ibrutinib than with chlorambucil (86% vs 35%)
[51, 52]. It is important to note that unlike RESONATE in
RESONATE 2, the presence of a 17p deletion was an exclu-
sion criterion, and the use of single-agent chlorambucil with-
out a CD20 antibody is now very rare. A more relevant com-
parison of ibrutinib versus bendamustine and rituximab in
patients over 65 did show ibrutinib to confer a significant
benefit. The estimated percentage of patients with
progression-free survival at 2 years was 74% with
bendamustine plus rituximab and 87% with ibrutinib alone.
FCR(BR if >65
years)
Young and fit
Obinutuzumab +/-
chlorambucil
Or
Ibrutinib
Untreated CLL patient 
who meets the criteria 
for therapy
Assess TP53 
status
TP53 mutated
Ibrutinib
Assess IGHV 
mutation status
IGHV not 
mutated
Old and/or frailIGHV mutated
Young and fit
Ibrutinib
Or
FCR(BR if >65years)
Ibrutinib
Or
Obinatuzumab 
Old and/or frail
Relapsed or 
refractory CLL
Restaging: bone marrow aspirate and biopsy, CT, FISH, TP53 
mutation analysis
Exclude Richter’s Transformation
Has patient 
progressed on 
ibrutinib?
Yes No
Venetoclax + rituximab
Ibrutinib 
Or
Venetoclax + 
rituximab
Fig. 1 Flow chart showing the
decision process and treatment
options in management of
previously untreated CLL that
meets the iwCLL criteria for
treatment and in relapsed or
refractory disease
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Combined rituximab and ibrutinib provided no additional
benefit compared with ibrutinib alone with an estimated PFS
of 88% at 2 years [53]. Ibrutinib and obinutuzumab does ap-
pear to be beneficial compared with CLB-obinutuzumab with
a high estimated 30-month overall survival and fewer serious
adverse events in the iLLUMINATE phase 3 trial of first-line
treatment [54] (Table 1).
The use of ibrutinib first line in younger patients, without
17p deletion or p53 mutation, has not yet been clearly dem-
onstrated, one trial has reported an improvement in PFS and
OSwith ibrutinib and rituximab comparedwith FCR as a first-
line treatment of CLL in patients under 70 [55]. However, as
of yet, there has only been a short follow-up period, and there
was a surprisingly high number of deaths in the FCR arm
indicating further work is needed.
The results of the RESONATE trials have not been rep-
licated in the clinic; the UK ibrutinib real world study
reported that 44% of the patients had a dose reduction,
interruption of complete cessation in the first 12 months
compared with 4% in the resonate study. The OS at
12 months was 83%, 89% for patients with no dose reduc-
tion or cessation of less than 14 days compared with 90%
in the RESONATE [56•]. A theoretical benefit of small
molecule inhibitors is the reduced side effect profile but
due to off-target effects, these are still not negligible with
significant bleeding, recurrent infections and cardiac
toxicity, particular atrial fibrillation, being the most com-
mon reasons for treatment interruption or cessation.
We are now beginning to understand the mechanisms under-
lying the ibrutinib failure to ibrutinib failure. Comparisons of
targeted deep sequencing before initiation of ibrutinib and at the
point or either CLL progression or Richter’s transformation
identified newmutations in BTK or PLG2 that were not present
prior to treatment [57]. A larger prospective study also
identified these mutations in some patients who had not yet
shown signs of clinical relapse suggesting sequencing may be-
come an indicator of when further intervention is required [58].
Phosphatidylinositol 3-Kinases(PI3K)
Inhibitors—Idelalisib
The PI3K signalling pathway, downstream of the B cell recep-
tor, is constitutively activated in CLL and is required for their
survival and proliferation [59, 60]. Idelalisib is a potent and
specific inhibitor of PI3K isoform expression of which is re-
stricted to cells of haematopoietic origin. Idelalisib induces
apoptosis in CLL cells whilst T cells and NK cell are unaffect-
ed. Like ibrutinib, idelalisib has multiple mechanisms of ac-
tion, such as disruption of the CLL cell CXC12 and CXC13
driven chemotaxis towards stromal cells and their migration
beneath them; this may keep the cells within the peripheral
Table 1 Significant randomised and more recent phase 1/2 trials using targeted small molecular inhibitors in CLL
Treatment FL/
RR
Number Age ORR NMRD 2YOS Reference
Randomised phase 3 trials
Ibrutinib RR 195 67 63% NR 1 year 90% Byrd 2014 [51]
Ofatumumab 196 67 4% NR 1 year 81%
Ibrutinib FL 136 73 86% NR 98% Burger 2015 [52]
Chorambucil 133 72 35% NR 85%
Ibrutinib FL 182 71 93% 1% 90% Woyach 2018 [53]
Ibrutinib/rituximab 182 71 94% 4% 94%
Ibrutinib/obinutuzumab FL 113 70 88% 35% 30 m 86% Moreno 2019 [54]
CLB/obinutuzumab 116 72 73% 25% 30 m 85%
Bendamustine/rituximab 183 70 81% 8% 95%
Ibrutinib/rituximab FL 354 58 96% 8% 3 years 99% Shanfelt 2019 [55]
FCR 175 57 81% 59% 3 years 92%
Idelalisib/rituximab RR 110 71 81% NR 1 year 92% Furman 2014 [62]
Rituximab 110 71 13% NR 1 year 80%
Venetoclax/rituximab RR 194 65 92% 62% 92% Seymour 2018 [68]
Bendamustine/rituximab 195 65 72% 13% 87%
Phase 1/2 trials
Ibrutinib/venetoclax FL 80 65 88% 61% 1 year 99% Jain 2019 [73]
Alcalabrutinib RR 61 62 95% NR 1 year 100% Byrd 2016 [75]
FL first-line therapy, RR relapsed or refractory, Agemedian in years,ORR overall response rate,NMRD negative MRD in peripheral blood, 2YOS 2-year
overall survival rate unless alternate follow-up period specified
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blood increasing their susceptibility to apoptosis induction
[60]. Idelalisib was initially evaluated in relapsed and refrac-
tory disease including patients with adverse features—bulky
lymphadenopathy, 17p deletion/Tp53 mutation, IGHV-
unmutated and failure of multiple treatments. Idelalisib had
an overall response rate of 72% in this cohort and PFS of
15.8 months [61]. The combination of idelalisib with rituxi-
mab, compared with rituximab alone, leads to higher overall
response rate 81%vs 13% and a 12-month survival or 92% vs
81%. There was also a higher rate of reported serious adverse
events in the idelalisib and rituximab group (40%)—the most
common being pneumonia, pyrexia and febrile neutropoenia;
it is likely that due to its toxicity, its use will be restricted to
relapsed disease [62].
BCL2 Inhibition—Venetoclax
An ability to evade apoptosis is required for the development
of cancer—making its regulatory pathways an important ther-
apeutic target [63]. Venetoclax, a BH3 mimic, prevents the
interaction between BCL2 and BH3 inducing cell death
[64]. Earlier BH3 mimetics showed good disease response
but induced severe thrombocytopaenia in a phase 1 trial
[65]. Venetoclax avoids this due to its higher specificity for
BCL2 than some of its predecessors. The phase 1 and 2 trials
of venetoclax showed impressive results with an overall re-
sponse rate of 70–80% across all prognostic groups including
patients with a 17p deletion/Tp53 mutation. Additionally, un-
like the use of ibrutinib and idelalisib, venetoclax-induced
MRD negative complete responses [66]. The most important
adverse effect was the occurrence of fatal tumour lysis syn-
drome in the initial phase 1 trial; this could occur after even a
single dose of 100 or 200 mg. Since the introduction of a strict
dosing increment regime, there have been no further deaths
attributable to, and a lower incidence of TLS. Monitoring for
cytopaenias, infection and hepatotoxicity is also required.
A retrospective analysis of the UK patients started on
venetoclax, who had failed a BTK inhibitor and/or a PI3K
inhibitor, reported an overall response rate of 88%. At the
median follow-up of 15·6 months, the 1-year PFS and OS
was 65.0% and 75.1%, respectively. Of particular interest
was the response rate of 80% in patients who had received
both BTK and PI3K inhibitors—a group of patients who pre-
viously had no further treatment options other than autologous
stem cell transplant [67]. A similar study conducted in the US
reported a lower ORR of 72%, but a much higher proportion
of patients therapy was held/stopped 29% compared with 8%
in the UK, and so far, the follow-up period has been signifi-
cantly shorter—7 months [3]. The use of venetoclax in com-
bination with monthly rituximab had a dramatically improved
outcome at 2 years compared with BR in relapsed CLL, and
this combination is now commonly used in clinical practice
[68••]. Interestingly, the VR regimes result in 62% of patients
having MRD negativity in peripheral blood, compared with
13% of the BR, hopefully longer follow-up will show that this
combination results in a durable remission. Venetoclax is not
immune to the development of resistance with identified
mechanisms being mutation of BCL2 or the compensatory
over expression of MCL1, another BCL family member [69,
70]. However with the promising MRD negativity seen in VR
regimes, it is hoped that combination therapy that includes
venetoclax may prevent the development of resistance and
treatment failure.
As the apoptotic pathways are targeted by venetoclax are
universal, there is hope its success in CLL will be replicated.
Within haematology, there have been promising results
supporting the use of venetoclax in combination with
hypomethylating agents such as daunorubicin in relapsed
AML or with cytidine analogues as a first-line treatment for
AML in older patients [71].
Conclusion—the Future of CLL Treatment
The last decade has seen dramatic change in CLL treatment
but there are important trial results awaited in 2020 and further
into the future. The watch and wait principle of CLL—
delaying treatment initiation until a progression means the
iwCLL criteria are met is from the chemoimmunotherapy
era. Several trials challenging this with the initiation of
ibrutinib at diagnosis in patients without an indication to treat
but high-risk disease are active, with results due to be reported
in mid-2020 or in ongoing recruitment [72, 73]. Additionally,
longer term follow-up in patients treated with small molecule
inhibitors is required to see if the achievement of MRD neg-
ativity improves survival as seen with FCR—it is likely that
monitoring MRD will become more common place in CLL,
as it is already in other haematological malignancies [74]. The
results of a multicentre phase 1/2 trials establishing the max-
imum tolerated dose of alcalabrutinib—a BTK inhibitor with
higher specificity and lower reversibility than ibrutinib—are
due to be published in early 2021 indicating that with time, we
will likely see an increase in the number of available drugs
within the classes of small molecule inhibitors already
established [75]. Perhaps, the most exciting current trials in
CLL are the use of multiple molecular inhibitors—such as
venetoclax and ibrutinib simultaneous—this combination
has been shown to provoke a complete remission, including
MRD negativity, in patients after a limited duration of treat-
ment meaning that patients may not be committed to indefinite
therapy [73••]. Limiting length of treatment regimens has the
advantageous of reduced exposure, and therefore, toxicity par-
ticularly relevant in CLL due to the increasingly complex co-
morbidities seen in this patient cohort. It is recommend that fit
patients with relapsed CLL, or a 17p deletion, should be
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considered for allogeneic transplantation after the failure of
one kinase inhibitor—whilst venetoclax provides a valid
option for these patients in the future CARTcells may also
prevent the need for transplant [76]. Small studies of anti-
CD19 CAR T cells in patients who relapsed on BTK
inhibitors have shown response rates of over 70% and a
survival rate of 100%, although only after 6 months of
follow-up. Further larger trials are required, but we can
be cautiously optimistic; this may provide a safer
alternative to transplantation in patients who fail small
molecule therapy [77, 78].
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